J Cardiovasc Pharmacol. 2022 Aug 23. doi: 10.1097/FJC.0000000000001364. Online ahead of print.
Only a few meta-analyses evaluated the effect of finerenone on cardiovascular events in type 2 diabetes mellitus (T2DM) with chronic kidney disease (CKD). The main aim of this meta-analysis was to gain more reliable assessments of the efficacy and safety of finerenone for prevention of cardiovascular events in diabetic kidney disease. We searched for finerenone in the treatment of diabetic kidney disease from database (PubMed, Embase and ClinicalTrials.gov) until December 30, 2021. Relative risks (RRs) with 95% confidence intervals (CIs) calculated by the Mantel-Haenszel random-effects model were used as summary statistics for the categorical data. We included four studies that met the inclusion criteria with 13,943 participants. The finerenone group demonstrated a great benefit in reducing the incidence of major adverse cardiac events (MACEs) (RR: 0.88; 95% CI 0.80 – 0.96; P = 0.003), all-cause mortality (RR: 0.89; 95% CI 0.80 – 0.99; P = 0.04), myocardial infarction (RR: 0.79; 95% CI 0.67 – 0.92; P = 0.003) and new-onset hypertension (RR: 0.71; 95% CI 0.62 – 0.81; P < 0.00001). No difference was found in adverse events between the finerenone and placebo groups (RR: 1.00; 95% CI [0.98, 1.01], P = 0.59), whereas, a higher risk of hyperkalemia was observed in the finerenone group than in the placebo group (RR = 2.04, 95% CI 1.80 – 2.32; P < 0.00001). Besides, cerebrovascular events and new-onset atrial fibrillation did not increase in patients taking finerenone. Overall, finerenone treatment showed a great benefit of reducing the risk of MACEs, all-cause mortality, myocardial infarction, and new-onset hypertension events in patients with T2DM and CKD.